Aller au contenu

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.

Nom du journal : JCO Precis Oncol

Année : 2023

Volume : 7

Page de départ : e2200436

Auteurs: Bokemeyer, C, Paracha, N, Lassen, U, Italiano, A, Sullivan, SD, Marian, M & al,